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Abstract
Introduction The rheumatoid arthritis (RA) synovium is
characterised by the presence of an aggressive population of
activated synovial fibroblasts (RASFs) that are prominently
involved in the destruction of articular cartilage and bone.
Accumulating evidence suggests that RASFs are relatively
resistant to Fas-ligand (FasL)-induced apoptosis, but the data
concerning tumour necrosis factor-related apoptosis-inducing
ligand (TRAIL) have been conflicting. Here, we hypothesise that
the susceptibility of RASFs to receptor-mediated apoptosis
depends on the proliferation status of these cells and therefore
analysed the cell cycle dependency of FasL- and TRAIL-induced
programmed cell death of RASFs in vitro.
Methods Synovial fibroblasts were isolated from patients with
RA by enzymatic digestion and cultured under standard
conditions. Cell cycle analysis was performed using flow
cytometry and staining with propidium iodide. RASFs were
synchronised or arrested in various phases of the cell cycle with
0.5 mM hydroxyurea or 2.5 g/ml nocodazol and with foetal calf
serum-free insulin-transferrin-sodium selenite supplemented
medium. Apoptosis was induced by stimulation with 100 ng/ml
FasL or 100 ng/ml TRAIL over 18 hours. The apoptotic
response was measured using the Apo-ONE® Homogenous
Caspase-3/7 Assay (Promega GmbH, Mannheim, Germany)
and the Cell Death Detection (ELISAPlus) (enzyme-linked
immunosorbent assay) (Roche Diagnostics GmbH, Mannheim,
Germany). Staurosporin-treated cells (1 g/ml) served as a
positive control. Expression of Fas and TRAIL receptors
(TRAILR1-4) was determined by fluorescence-activated cell
sorting analysis.
Results Freshly isolated RASFs showed only low proliferation in
vitro, and the rate decreased further over time, particularly when
RASFs became confluent. RASFs expressed Fas, TRAIL
receptor-1, and TRAIL receptor-2, and the expression levels
were independent of the cell cycle. However, the proliferation
rate significantly influenced the susceptibility to FasL- and
TRAIL-induced apoptosis. Specifically, proliferating RASFs
were less sensitive to FasL- and TRAIL-induced apoptosis than
RASFs with a decreased proliferation rate. Furthermore, RASFs
that were synchronised in S phase or G2/M phase were less
sensitive to TRAIL-induced apoptosis than synchronised RASFs
in G0/G1 phase.
Conclusions Our data indicate that the susceptibility of RASFs
to FasL- and TRAIL-induced apoptosis depends on the cell
cycle. These results may explain some conflicting data on the
ability of RASFs to undergo FasL- and TRAIL-mediated cell
death and suggest that strategies to sensitise RASFs to
apoptosis may include the targeting of cell cycle-regulating
genes.
2 n DNA: diploid chromosomes; 4 n DNA: tetraploid chromosomes; DMEM: Dulbecco's modified Eagle's medium; EDTA: ethylenediaminetetraacetic 
acid; ELISA: enzyme-linked immunosorbent assay; FACS: fluorescence-activated cell sorting; FasL: Fas ligand; FCS: foetal calf serum; HU: hydrox-
yurea; ITS: insulin-transferrin-sodium selenite; NF-B: nuclear factor-kappa-B; OD: optical density; PBS: phosphate-buffered saline; RA: rheumatoid 
arthritis; RASF: rheumatoid arthritis synovial fibroblast; RFU: relative fluorescence units; TNF: tumour necrosis factor; TRAIL: tumour necrosis factor-
related apoptosis-inducing ligand.Arthritis Research & Therapy    Vol 11 No 1    Pundt et al.
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Introduction
Rheumatoid arthritis (RA), a chronic disease of incompletely
understood aetiology, is characterised primarily by the pro-
gressive destruction of articular structures. Its pathogenesis is
governed by the concerted action of several cell types that
create signs and symptoms characteristic for RA. Accumulat-
ing evidence indicates that, in addition to macrophages and T
cells, activated RA synovial fibroblasts (RASFs) play a major
role in both initiating and driving the disease [1-4]. Not only do
RASFs with an aggressive phenotype increase in number,
their activation also results in the production of proinflamma-
tory mediators and matrix-degrading enzymes and in altera-
tions of programmed cell death [3-5].
Programmed cell death, or apoptosis, is central for both devel-
opment and tissue homeostasis of metazoans. Therefore,
aberrations of this process may lead to a variety of human
pathologies, including cancer, autoimmune diseases, and neu-
rodegenerative disorders. Apoptosis can be induced by mem-
bers of the tumour necrosis factor (TNF) receptor family
through the recruitment of an intracellular membrane-associ-
ated complex of proteins (death-inducing signaling com-
plexes, or DISCs), which leads to a cytoplasmic release of
active caspase-8 and subsequent activation of the apoptotic
cascade [6,7]. Among these death receptors, Fas/CD95 and
its specific ligand FasL/CD95L were demonstrated to be of
importance, and it was shown that stimulation of RASFs with
FasL initiates proapoptotic signals [8,9]. However, several
studies with cultured RASFs showed that stimulation of
RASFs with Fas-activating ligands induced apoptosis in only a
small percentage of cells, and several mechanisms have been
identified that prevent RASFs from Fas-mediated cell death
[10-16]. Actually, several studies have shown that RASFs
undergo less FasL-induced apoptosis than osteoarthritis syn-
ovial fibroblasts and therefore RASFs has been termed rela-
tively resistant to FasL-induced apoptosis. As shown
previously, fibroblasts in RA synovium express both TNF-
receptors and Fas, and their ligands have been detected in co-
localised macrophages and T cells [17-19].
TNF-related apoptosis-inducing ligand (TRAIL), another mem-
ber of the TNF superfamily of apoptosis-inducing ligands, can
bind to five receptors. Among them, TRAIL-R3 (DcR1) and
TRAIL-R4 (DcR2) act as membrane-anchored decoy recep-
tors, whereas TRAIL-R1 (DR4) and TRAIL-R2 (DR5) contain a
cytoplasmic death domain and transmit proapoptotic signals
into cells [20]. In addition, osteoprotegerin, a soluble decoy
receptor of the ligand for the receptor activator of nuclear fac-
tor-kappa-B (NF-B) (RANKL), has been shown to bind TRAIL
[21,22]. Apoptosis can be induced upon binding of TRAIL to
DR4 and DR5 and subsequent activation of different cas-
pases. On the other hand, studies suggest that binding of
TRAIL to these receptors can also induce proliferation through
activation of the NF-B signalling pathway [23,24], and it
appears that the ability of TRAIL to trigger either apoptosis or
cell survival depends on the cell type [25].
The  in vitro data concerning TRAIL-induced apoptosis in
RASFs have been conflicting. Morel and colleagues [25]
showed that exposure to TRAIL induced apoptosis in only
30% of RASFs within 24 hours whereas surviving cells prolif-
erated in a TRAIL dose-dependent manner. In contrast,
Ichikawa and colleagues [26] documented TRAIL (anti-DR5
antibody)-induced apoptosis of RA synovial cells with 80% of
the cells being killed. In both studies, RASFs showed consti-
tutive expression of TRAIL receptor-2 (DR5) as the main medi-
ator of TRAIL-induced stimulation. In addition, Morel and
colleagues [25] could show the expression of TRAIL-R1
(DR4). Here, we hypothesise that the susceptibility of RASFs
to receptor-mediated apoptosis depends on the proliferation
state of these cells. Therefore, we analysed the cell cycle
dependency of FasL- and TRAIL-induced programmed cell
death of RASFs in vitro.
Materials and methods
Patients and tissue samples
Samples of synovial membrane from patients with RA (accord-
ing to the 1987 revised American College of Rheumatology
criteria) were obtained at joint replacement surgery within an
ongoing national tissue bank project with the 'Assoziation für
Rheumatologische Orthopädie' (ARO) of the German Society
of Rheumatology (DGRh) and provided by the Department of
Orthopaedic Surgery of St. Joseph Hospital (Sendenhorst,
Germany), the Department of Orthopaedic Surgery of the Uni-
versity of Magdeburg School of Medicine (Magdeburg, Ger-
many), and the Department of Orthopaedic Surgery (KMG-
Kliniken Kyritz, Germany). Approval from the local ethics com-
mittee was obtained prior to starting the study. Fibroblasts
were isolated by digesting synovial tissue with 1.5 mg/ml Dis-
pase II (Roche Diagnostics GmbH, Mannheim, Germany) and
cultured in complete Dulbecco's modified Eagle's medium
(DMEM supplemented with 10% foetal calf serum [FCS], Inv-
itrogen Corporation, Carlsbad, CA, USA, and penicillin/strep-
tomycin, PAA, Pasching, Austria) as described previously
[27]. Fibroblasts were used in passages 4 to 8.
Fluorescence-activated cell sorting analysis
Flow cytometric analysis of cell cycle was performed as
described previously [28]. Briefly, cells were detached with 1
mM ethylenediaminetetraacetic acid (EDTA) and suspended
in fluorescence-activated cell sorting (FACS) buffer (phos-
phate-buffered saline [PBS] supplemented with 5% FCS and
0.1% NaN3). Cell cycle analysis was performed by incubation
of cells with propidium iodide (40 g/ml propidium iodide, 100
g/ml RNase in PBS) for up to 2 days and subsequent flow
cytometry (FACScalibur; BD Biosciences, San Jose, CA,
USA). To arrest RASFs in G2/M phase, cells were treated with
nocodazol (2.5 g/ml in DMEM for 18, 24, or 36 hours; Calbi-
ochem, Darmstadt, Germany). Furthermore, randomly growingAvailable online http://arthritis-research.com/content/11/1/R16
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cultures of RASFs were synchronised with 0.5 mM hydroxyu-
rea (HU) (Sigma-Aldrich, Steinheim, Germany) in DMEM and
incubated at 37°C for 6 hours. Cells were washed with PBS
and suspended in fresh complete DMEM. Synchronised
RASFs were incubated at 37°C and samples (0, 18, 24, 30,
42, and 48 hours) thereof were analysed for cell cycle by pro-
pidium iodide staining as described above. In addition, RASFs
were arrested in G0/G1 phase by serum deprivation. To this
end, cultures of RASFs were incubated with DMEM supple-
mented with 1× insulin-transferrin-sodium selenite (ITS) sup-
plement (100×) (Sigma-Aldrich) [29,30] for up to 10 days (0,
3, 8, and 10 days) following incubation with complete medium
for 1 or 2 days (9/1, 9/2 days).
Analysis of Fas- and TRAIL-receptor expression
Surface expression of Fas and TRAIL receptors (TRAILR1-4)
on RASFs was determined by flow cytometry as described
[31]. Briefly, 1 × 105 cells were labelled with 0.5 g of mouse
anti-TRAILR1-4 (Alexis Biochemicals, Lörrach, Germany),
mouse anti-Fas antibodies, or mouse anti-IgG in FACS buffer
containing 5 mM EDTA for 40 minutes at 4°C. These cells
were incubated with biotin-conjugated goat anti-mouse, phy-
coerythrin-conjugated anti-goat, or fluorescein isothiocyanate-
conjugated anti-mouse antisera for 30 minutes at 4°C. Stained
cells were fixed and 1 × 104 viable cells were analysed by flow
cytometry using standard settings.
Induction and measurement of apoptosis
Apoptosis was induced at different density states or cell cycle
phases by incubation of cells with 100 ng/ml FasL (Bender
MedSystems, Vienna, Austria) or 100 ng/ml TRAIL (Pepro
Tech, Rocky Hill, NJ, USA) in 100 L of complete DMEM or
DMEM for 18 hours. The apoptotic response was measured
by Cell Death Detection (ELISAPlus) (enzyme-linked immuno-
sorbent assay) (Roche Diagnostics GmbH) and the Apo-
ONE® Homogeneous Caspase-3/7 Assay (Promega GmbH,
Mannheim, Germany) in accordance with the instructions of
the manufacturer. Staurosporin-treated cells (1 g/ml, 8
hours) served as a positive control.
Statistical analysis
Data shown are mean ± standard deviation. Statistical analysis
was performed using GraphPad Prism Software version 4.0
(GraphPad Software Inc., San Diego, CA, USA). Differences
between groups were examined for statistical significance
using the Mann-Whitney test, and a P value of less than 0.05
was considered statistically significant.
Results
Proliferation of rheumatoid arthritis synovial fibroblasts
First, we analysed DNA content by FACS analysis to deter-
mine the proliferation rate of RASFs. Early-cultured RASFs
exhibited a proliferation rate of 13.01%, according to cells
with a DNA content of greater than 2 n (Figure 1a, represent-
ative histogram, and Figure 1c, DNA content in S and G2/M
phases, n = 11). ~2 n DNA refers to the normal DNA content
in the interphase (G0/G1 phase, diploid) of RASFs [32]. Con-
fluent RASFs (100% confluent, 104 cells) exhibited a prolifer-
ation rate of 6.53% (Figure 1b, representative histogram, and
Figure 1c, n = 5), significantly lower compared with early-cul-
tured RASFs (Figure 1c, P = 0.0028). Nocodazol, the micro-
tubule-destabilising agent that disrupts spindle assembly and
impedes re-entry into the cell cycle [32,33], was used to arrest
RASFs at G2/M phase (~4 n DNA). Cell cycle analysis of early-
cultured RASFs (104 cells) treated with nocodazol for 18
hours showed only a marginal increase of proliferating RASFs
to G2/M phase, from 7.95% to 11.41%, corresponding to ~4
n DNA content (Figure 2a, representative histogram, and Fig-
ure 2b, n = 5). Similar results were obtained after incubation
with nocodazol for 24 and 36 hours (data not shown). MHH-
ES-1 cells, an established Ewing sarcoma cell line [34], were
used as a positive control for arresting cells in G2/M phase
after incubation with nocodazol. G2/M-phase-arrested MHH-
ES-1 cells showed a 20% increase in the G2/M phase, from
46% to 66% (data not shown). HU, which inhibits reversible
DNA synthesis in mammalian cells without affecting RNA and
protein synthesis, was used to synchronise RASFs in G0/G1
phase [35]. The effect of HU on the cell cycle of RASFs was
illustrated in Figure 2c (representative histogram) and Figure
2d (n = 3). Cell cycle analysis of RASFs treated with a single
exposure to 0.5 mM HU for 6 hours (time 0 hours) showed an
accumulation of RASFs in G0/G1  phase (93.39%, corre-
sponding to ~2 n DNA, n = 3), indicating that the cell popula-
tion remained highly synchronised. Figure 2c and 2d also
illustrated the cell cycle of RASFs after various hours after
reversal of HU. Analysis of cell cycle 18, 24, 30, 42, and 48
hours after HU exposure showed a decrease of RASFs in G0/
G1 phase until 66.24% (-27.15%, after 24 hours, n = 3) with
simultaneous increase of proliferating RASFs in S phase,
reaching a maximum at 24 hours (+11.55%, n = 3), and G2/M
phase, reaching a maximum at 30 hours (+25.53%, ~4 n
DNA, n = 3). Forty-two hours after HU exposure, cell cycle
analysis confirmed an increase of RASFs in G0/G1 phase back
to 87.18%, and after 48 hours to 89.83%, indicating that cell
division commenced between 30 and 48 hours. No higher
degree of synchronisation was induced by a subsequent sec-
ond exposure to HU (data not shown). In addition, RASFs
were arrested in G0/G1  phase through serum deprivation
using ITS supplement. As illustrated in Figure 2e (representa-
tive histogram) and Figure 2f (n = 3), early-cultured RASFs
became arrested at G0/G1 phase after 8 to 10 days of incuba-
tion with ITS medium. The initial rate of proliferating RASFs
decreased from 11.14% to 8.56%, or 7.96% (corresponding
to <2 n DNA, from 0 d to 8 d, and 10 d, n = 3). Subsequent
incubation for another one or two days with complete DMEM
resulted in an increase of proliferating RASFs to 25.95% (<2
n DNA, 9 days of ITS medium/1 day of complete medium, 9/1
d) or 22.34% (9/2 d). Maximum of RASFs in S phase was
reached at day 9/1 (+12.02%, n = 3) and in G2/M phase atArthritis Research & Therapy    Vol 11 No 1    Pundt et al.
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day 9/2 (+11.3%, n = 3). These results suggest that only a
small population of early-cultured RASFs proliferate.
Susceptibility of rheumatoid arthritis synovial 
fibroblasts to FasL- and TRAIL-induced apoptosis
Next, we analysed the cell cycle dependency of FasL- and
TRAIL-induced programmed cell death of RASFs in vitro. We
found that higher-proliferating RASFs (50% of confluency)
from different patients were less sensitive to TRAIL-induced
apoptosis than lower-proliferating RASFs (80% of confluency)
and even significantly less sensitive when confluent RASFs
(100% confluent) were used as measured by Cell Death
Detection (ELISAPlus). As Figure 3a illustrates, the photometric
enzyme immunoassay for the detection of cytoplasmic his-
tone-associated DNA fragments showed a reduction from
3.35 relative fluorescence units (RFU) (confluent RASFs) to
1.55 RFU (-53%, lower-proliferating RASFs) or to 1.0 RFU (-
70.15%, higher-proliferating RASFs, data are presented as
optical density (OD)/OD untreated RASFs, n = 7). Similar
observations were made when RASFs in different density
states were treated with FasL. Measurement of the activities of
caspase-3 and caspase-7, key effectors of apoptosis in mam-
malian cells, revealed that higher-proliferating RASFs (50% of
confluency) were less sensitive to FasL-induced apoptosis
than lower-proliferating RASFs (80% of confluency) and con-
fluent RASFs (Figure 3b). A reduction from 6.79 × 104 RFU
(confluent RASFs) to 5.26 × 104 RFU (-22.5%, lower-prolifer-
ating RASFs) and to 2.8 × 104 RFU (-59%, higher-proliferating
RASFs, n = 3) was observed. Furthermore, highly synchro-
nised RASFs in S phase (HU, time 24 hours, Figure 2c,d) and
in G2/M phase (time 30 hours) were less sensitive to TRAIL-
induced apoptosis than synchronised RASFs in G0/G1 phase
(time 0 hours, Figure 3c). A reduction from 4.84 × 104 RFU
(HU/0 hours, n = 5) to 1.83 × 104 RFU (-62.2%, HU/24 hours,
n = 5) or to 1.93 × 104 RFU (-60.13%, HU/30 hours, n = 5)
was observed by measurement of the activities of caspase-3
and caspase-7. Similar results were obtained after measure-
ment of FasL-induced apoptosis. Compared with RASFs syn-
chronised in G0/G1 phase (7.06 × 104 RFU, n = 3, Figure 3d),
RASFs synchronised in S phase showed a reduced apoptotic
response of 1.2 × 104 RFU (-83.01%, n = 3) and RASFs syn-
chronised in G2/M phase showed a reduced apoptotic
response of 1.45 × 104 RFU (-79.5%, n = 3). Moreover,
RASFs arrested in G0/G1 phase through serum deprivation
using ITS medium (8 d) were more sensitive to TRAIL- and
FasL-induced apoptosis than proliferating RASFs in S phase
(9/1 d) or in G2/M phase (9/2 d, Figure 3e,f). TRAIL-induced
caspase-3/7 activities decreased from 8.62 × 104 RFU in
RASFs arrested in G0/G1 phase to 1.15 × 104 RFU (-86.6%,
n = 3) in RASFs arrested in S phase and to 1.54 × 104 RFU (-
82.1%, n = 3) in RASFs arrested in G2/M phase. Again, com-
parable results were obtained by measurement of FasL-
induced programmed cell death. Figure 3f illustrates a reduc-
tion from 1.14 × 106 RFU (G0/G1 phase, 8 d) to 0.61 × 105
RFU (-94.64%, S phase, 9/1 d) and to 5.52 × 105 RFU (-
51.84%, G2/M phase, 9/2 d). Unless otherwise noted, all data
Figure 1
Proliferation capacity of rheumatoid arthritis synovial fibroblasts  (RASFs) Proliferation capacity of rheumatoid arthritis synovial fibroblasts 
(RASFs). (a) Early-cultured RASFs exhibit only a very low proliferation 
rate in vitro (>2 n DNA equates S phase and G2/M phase, representa-
tive histogram). ~2 n DNA (arrow at 200) refers to the normal DNA 
content of interphase (G0/G1 phase) RASFs [32]. 4 n DNA (arrow at 
G2/M peak at 400) refers to twice the amount of DNA in G2/M com-
pared with G0/G1 phase. (b) Decrease in proliferation rate in confluent 
RASFs. (c) Quantitative analysis. Values are mean ± standard deviation 
as a percentage of early-cultured and confluent RASFs obtained from 
11 or 6 individual patients with rheumatoid arthritis. **P < 0.01.Available online http://arthritis-research.com/content/11/1/R16
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Figure 2
Effects of synchronisation and cell cycle arrest on proliferation of rheumatoid arthritis synovial fibroblasts (RASFs) Effects of synchronisation and cell cycle arrest on proliferation of rheumatoid arthritis synovial fibroblasts (RASFs). (a) The effect of nocodazol on the 
cell cycle of early-cultured RASFs. Treatment of higher-proliferating RASFs with nocodazol (2.5 g/ml, 18 hours) resulted in a marginal increase of 
RASFs arrested in G2/M phase (~4 n DNA at G2/M peak, black line, representative histogram). (b) Quantitative analysis. Values are mean ± stand-
ard deviation as a percentage of RASFs treated/untreated with nocodazol obtained from 3 individual patients with RA. (c) Effects of hydroxyurea 
(HU) on cell cycle of RASFs were illustrated in a representative three-dimensional histogram with the y-axis (time in hours) pointing away from the 
observer. RASFs treated with HU for 6 hours (time 0 hours) showed an accumulation of RASFs in G0/G1 phase. Analysis of cell cycle 18, 24, and 
30 hours after HU exposure showed a decrease of RASFs in G0/G1 phase with a simultaneous increase of proliferating RASFs in S phase and G2/
M phase, indicating that the cell population remained highly synchronised. Cell cycle analysis after 42 and 48 hours confirmed an increase of RASFs 
in G0/G1 phase, indicating that cell division commenced between 30 and 48 hours. (d) Quantitative analysis as mean ± standard deviation. (e) 
Early-cultured RASFs became arrested at G0/G1 phase after 8 to 10 days of incubation with ITS medium. Subsequent incubation for another 1 or 2 
days with complete Dulbecco's modified Eagle's medium (9/1, 9/2 days) resulted in an increase of proliferating RASFs. Bar graphs in frames on 
right show quantitative analysis. Values are presented as mean ± standard deviation of percentages of RASFs obtained from at least three individual 
patients with rheumatoid arthritis. Representative three-dimensional histogram. (f) Quantitative analysis.Arthritis Research & Therapy    Vol 11 No 1    Pundt et al.
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in Figure 3 are presented as OD/OD unstimulated RASFs.
Staurosporin-treated cells served as a positive control. We
hypothesise that the susceptibility of RASFs to receptor-medi-
ated apoptosis depends on the proliferation state of these
cells in vitro.
Expression of Fas and TRAIL receptors on rheumatoid 
arthritis synovial fibroblasts
Finally, to investigate whether altered expression of death
receptors may provide an explanation for differences in the
susceptibility of RASFs to FasL- and TRAIL-induced apopto-
sis, the expression of Fas- and TRAIL-receptor changes during
cell cycle progression, synchronisation, or at cell cycle arrest
was examined. As shown by flow cytometry, TRAIL-R1 and
TRAIL-R2 were expressed constitutively on higher-proliferat-
ing RASFs in vitro, whereas TRAIL-R3 and TRAIL-R4 were not
detectable. The expression levels did not change in confluent
RASFs (Figure 4a, representative histogram, n = 3). In addi-
tion, expression of these receptors was unaltered when
RASFs were treated for 18 hours with 100 ng/ml TRAIL (data
not shown). Furthermore, cell surface expression of TRAIL
receptors on RASFs remained unchanged in RASFs synchro-
nised with HU (Figure 4b, representative histogram, n = 3) or
on RASFs arrested by using ITS medium (data not shown).
Fas (CD95) is a well-known apoptosis-signalling cell surface
receptor belonging to the TNF receptor family [36]. To investi-
gate the susceptibility of RASFs to FasL-mediated apoptosis,
cell surface expression of Fas on RASFs was determined by
flow cytometry in vitro. In agreement with data from Kobayashi
and colleagues [37], who showed surface expression of Fas
on RA synoviocytes, Fas was constitutively expressed on
higher-proliferating RASFs (data not shown). Cell surface
expression remained unchanged in confluent RASFs and
under all investigated conditions (data not shown).
Discussion
A decreased susceptibility to apoptosis and synovial prolifera-
tion has been described to contribute to RASF hyperplasia
[5,10,11,14,38,39]. In this context, the TRAIL receptor/TRAIL
system and the Fas/FasL system have raised much interest.
Increasing evidence suggests that RASFs are relatively resist-
ant to FasL-induced apoptosis in vitro [10,11,40]. Specifically,
several studies with cultured RASFs showed that synovio-
cytes from rheumatoid synovium tissue express functional Fas
[8,17,18] and that Fas activation induces apoptosis only in a
small population of cells, even though the Fas/FasL system
seems to be incapable of eliminating cells in proliferative RA
synovium [8,18,37,40,41]. The data concerning TRAIL appear
to be controversial [25,26,40]. Ichikawa and colleagues [26]
analysed the effect of TRAIL on RASFs and reported an
increased DR5 expression and an induction of DR5-mediated
apoptosis up to 80%, although varying levels of apoptosis
were induced by TRAIL using different RASF cultures. In
agreement with these findings, Miranda-Carus and colleagues
[38] analysed fibroblasts of 50 RA synovial fluid samples and
showed that these fibroblasts underwent apoptosis when
treated in vitro with an agonistic anti-DR5 antibody. In con-
trast, Morel and colleagues [25] proposed that TRAIL might
have two different effects on RASFs, namely an initial rapid
induction of apoptosis of up to 30% within the first 24 hours
followed by an increase in the proliferation [25]. In addition, it
is well documented that, depending on the cellular system,
TRAIL can promote both proliferation and apoptosis, as has
been established for other members of the TNF cytokine family
[42]. In the present study, we hypothesised that the suscepti-
bility of RASFs to receptor-mediated apoptosis depends on
the proliferation status of these cells and, therefore, analysed
the cell cycle dependency of FasL- and TRAIL-induced pro-
grammed cell death of RASFs in vitro.
Our results indicate that freshly prepared RASFs exhibit only a
very low proliferation rate in vitro. The proliferation rate
decreases further over time, particularly when RASFs become
confluent. Furthermore, we describe for the first time that up to
65% of RASFs exhibit a G0/G1-phase arrest in vitro. Moreo-
ver, our study shows that early-cultured RASFs are less sensi-
tive to TRAIL- and FasL-induced apoptosis than late-cultured
RASFs and far less sensitive than 100% confluent RASFs.
The difference in sensitivity to TRAIL- and FasL-mediated
apoptosis between early-cultured and confluent RASFs is not
due to differences in the surface expression of Fas and TRAIL
receptors. Rather, the susceptibility clearly depended on the
cell cycle of these cells as RASFs that were synchronised in S
phase or G2/M phase were less sensitive to TRAIL-induced
apoptosis than RASFs that were arrested in G0/G1 phase.
These results suggest an inverse correlation between cell pro-
liferation and apoptosis. However, how the proliferation influ-
ences TRAIL- and FasL-mediated synovial cell death remains
unclear. Miyashita and colleagues [43] proposed that the ser-
ine/threonine protein kinase Akt, which affects several impor-
tant cellular functions (including cell growth, cell cycle entry,
migration, and cell survival), is an endogenous inhibitor of the
TRAIL-mediated synovial cell apoptotic pathway. Furthermore,
numerous data have shown that activation of Akt inhibits
TRAIL-mediated apoptosis in various cancer cells and Akt has
been shown to be overexpressed and activated in rheumatoid
synovial cells in situ [44-47]. Therefore, it might be speculated
that there is a correlation between cell proliferation and apop-
tosis, which may be regulated by the Akt pathway, but clearly
further studies are required to elaborate on these
observations.
Conclusion
In summary, we have shown that a relatively high number of
RASFs are arrested in G0/G1 phase. Furthermore, our data
indicate that the sensitivity to TRAIL- or FasL-mediated apop-
tosis may be closely linked to synovial proliferation. These find-
ings will further enhance our understanding of the
pathophysiology of RA.Available online http://arthritis-research.com/content/11/1/R16
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Figure 3
Susceptibility of proliferating rheumatoid arthritis synovial fibroblasts (RASFs) to Fas ligand (FasL)-induced and tumour necrosis factor-related apop- tosis-inducing ligand (TRAIL)-induced apoptosis Susceptibility of proliferating rheumatoid arthritis synovial fibroblasts (RASFs) to Fas ligand (FasL)-induced and tumour necrosis factor-related apop-
tosis-inducing ligand (TRAIL)-induced apoptosis. (a) As assessed by Cell Death Detection (ELISAPlus), higher-proliferating RASFs (50% of conflu-
ency) were less sensitive to TRAIL-induced apoptosis than lower-proliferating RASFs (80% of confluency) and significantly less sensitive than 
confluent RASFs (100% confluent). (b) As revealed by the Apo-ONE® Homogeneous Caspase-3/7 Assay, higher-proliferating RASFs showed 
lower activities of caspase-3 and caspase-7 after induction of apoptosis with FasL than less-proliferating RASFs and confluent RASFs. Highly syn-
chronised RASFs in S phase (HU/24 h) or G2/M phase (HU/30 h) were less sensitive to TRAIL-induced (c) and FasL-induced (d) apoptosis than 
synchronised RASFs in G0/G1 phase (HU/0 h), as measured by the Apo-ONE® Homogeneous Caspase-3/7 Assay. Moreover, RASFs arrested in 
G0/G1 phase through serum deprivation using insulin-transferrin-sodium selenite (ITS) medium (8 d) were more sensitive to TRAIL-induced (e) and 
FasL-induced (f) apoptosis than proliferating RASFs in S phase (9/1 d) or G2/M phase (9/2 d). Staurosporin-induced apoptosis was measured as a 
positive control. All values are mean ± standard deviation of fluorescence/fluorescence of unstimulated RASFs from at least three independent 
patients with rheumatoid arthritis. *P < 0.05, **P < 0.01, ***P < 0.001.Arthritis Research & Therapy    Vol 11 No 1    Pundt et al.
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Figure 4
Surface expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors on rheumatoid arthritis synovial fibroblasts  (RASFs) Surface expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors on rheumatoid arthritis synovial fibroblasts 
(RASFs). (a) Staining of TRAIL receptors, as analysed by flow cytometry, showed constitutive surface expression of TRAIL-R1 and TRAIL-R2 on 
RASFs in vitro. TRAIL-R3 and TRAIL-R4 were not detectable. The expression levels did not change in confluent RASFs. (b) Furthermore, cell sur-
face expression of TRAIL-R1 and TRAIL-R3 on RASFs remained unchanged in RASFs synchronised with hydroxyurea (HU). Representative histo-
grams of three separate experiments are shown.Available online http://arthritis-research.com/content/11/1/R16
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